UK-based drugmaker GSK (LSE: GSK) has secured approval in its home country for the breakthrough respiratory syncytial virus (RSV) vaccine, Arexvy (respiratory syncytial virus vaccine).
The Medicines and Healthcare products Regulatory Agency (MHRA) has given its blessing for GSK to market the product for active immunization of people over the age of 60.
The vaccine is used to prevent lower respiratory tract disease caused by RSV, a common virus that leads to an estimated 175,000 visits to the doctor and up to 8,000 deaths among older people in the UK each year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze